Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: Results from a phase 3 clinical trial (LOTUS)

Journal of Drugs in Dermatology

Volumn 12, Issue 2, 2013, Pages 166-174

  Zhu, Xuejun ^a   Zheng, Min ^b   Song, Michael ^c   Shen, Yaung Kaung ^c   Chan, Daphne ^c   Szapary, Philippe O ^c   Wang, Baoxi ^d  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; USTEKINUMAB;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ARTHRALGIA; ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHINESE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FOLLOW UP; HEART INFARCTION; HUMAN; INFECTION; INJECTION SITE REACTION; LEUKOPENIA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEOPLASM; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PRURITUS; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, PSORIATIC; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PATIENT SAFETY; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SKIN;

EID: 84873341188     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Schön MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352(18):1899- 1912.
2. Zhang X, Wang H, Te-shao H, Yang S, Chen S. The genetic epidemiology of psoriasis vulgaris in Chinese Han. Int J Dermatol. 2002;41(10):663-669.
3. Liao HT, Lin KC, Chang YT, et al. Human leukocyte antigen and clinical and demographic characteristics in psoriatic arthritis and psoriasis in Chinese patients. J Rheumatol. 2008;35(5):891-895.
4. Ding X, Wang T, Shen Y, et al. Prevalence of psoriasis in China: a populationbased study in six cities. Eur J Dermatol. 2012;22(5):663-667.
5. Lin YK, Wong WR, Chang YC, et al. The efficacy and safety of topically applied indigo naturalis ointment in patients with plaque-type psoriasis. Dermatology. 2007;214(2):155-161.
6. Tse WP, Che CT, Liu K, Lin ZX. Evaluation of the anti-proliferative properties of selected psoriasis-treating Chinese medicines on cultured HaCaT cells. J Ethnopharmacol. 2006;108(1):133-141.
7. Tse TW. Use of common Chinese herbs in the treatment of psoriasis. Clin Exp Dermatol. 2003;28(5):469-475.
8. Koo J, Arain S. Traditional Chinese medicine for the treatment of dermatologic disorders. Arch Dermatol. 1998;134(11):1388-1393.
9. Tran D, Kwok YK, Goh CL. A retrospective review of PUVA therapy at the National Skin Centre of Singapore. Photodermatol Photoimmunol Photomed. 2001;17(4):164-167.
10. Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol. 2005;152(4):597-615.
11. Stern RS, Fitzgerald E, Ellis CN, Lowe N, Goldfarb MT, Baughman RD. The safety of etretinate as long-term therapy for psoriasis: results of the etretinate followup study. J Am Acad Dermatol. 1995;33(1):44-52.
12. Wu Y, Lin Y, Liu HJ, Huang CZ, Feng AP, Li JW. Childhood psoriasis: a study of 137 cases from central China. World J Pediatr. 2010;6(3):260-264.
13. Ho SG, Yeung CK, Chan HH. Methotrexate versus traditional Chinese medicine in psoriasis: a randomized, placebo-controlled trial to determine efficacy, safety and quality of life. Clin Exp Dermatol. 2010;35(7):717-722.
14. Thaç D. Long-term data in the treatment of psoriasis. Br J Dermatol. 2008;159 Suppl 2:18-24.
15. Griffiths CE, Clark CM, Chalmers RJ, Li Wan Po A, Williams HC. A systematic review of treatments for severe psoriasis. Health Technol Assess. 2000;4(40):1-125.
16. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP; Alefacept Clinical Study Group. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2002;47(6):821-833.
17. Papp KA, Tyring S, Lahfa M, et al Etanercept Psoriasis Study Group. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152(6):1304-1312.
18. Reich K, Nestle FO, Papp K, et al; EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367-1374.
19. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106-115.
20. Leonardi CL, Kimball AB, Papp KA, et al; PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665- 1674.
21. Papp KA, Langley RG, Lebwohl M, et al; PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675- 1684.
22. Huang Q, Yang QP, Fang X, et al. Treatment of psoriasis vulgaris with a recombinant human tumor necrosis factor receptor: Fc fusion protein: a multicentre, randomized, double blind trial. Chin J Dermatol. 2007;40(11):655-658.
23. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496-509
24. Chiu HY, Huang PY, Jee SH, et al. HLA polymorphism among Chinese patients with chronic plaque psoriasis: subgroup analysis. Br J Dermatol. 2012;166(2):288-297.
25. Wu Y, Lu Z, Chen Y, Xue F, Chen X, Zheng J. Replication of association between interleukin-23 receptor (IL-23R) and its ligand (IL-12B) polymorphisms and psoriasis in the Chinese Han population. Hum Immunol. 2010;71(12):1255-1258.
26. Chang YT, Chou CT, Yu CW, et al. Cytokine gene polymorphisms in Chinese patients with psoriasis. Br J Dermatol. 2007;156(5):899-905.
27. Krueger GG, Langley RG, Leonardi C, et al CNTO 1275 Psoriasis Study Group. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356(6):580-592.
28. Griffiths CE, Strober BE, van de Kerkhof P, et al ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118-128.
29. Igarashi A, Kato T, Kato M, Song M, Nakagawa H; Japanese Ustekinumab Study Group. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol. 2012;39(3):242-252.
30. Tsai TF, Ho JC, Song M, et al PEARL Investigators. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci. 2011;63(3):154-163.
31. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-244.
32. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol.1994;19(3):210- 216.
33. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005;152(5):861-867.
34. Lin XR. Psoriasis in China. J Dermatol. 1993;20(12):746-755.
35. Tam LS, Leung YY, Li EK. Psoriatic arthritis in Asia. Rheumatology (Oxford). 2009;48(12):1473-1477.
36. Yang Q, Qu L, Tian H, et al. Prevalence and characteristics of psoriatic arthritis in Chinese patients with psoriasis. J Eur Acad Dermatol Venereol. 2011;25(12):1409-1414.
37. Tuberculosis. World Health Organization Web site. http://www.who.int/ mediacentre/factsheets/fs104/en/index.html. Accessed May 24, 2012.
38. Hu Y, Zhao Q, Graviss EA, Jiang W, Yuan Z, Xu B. Use of the T-SPOT.TB assay to screen latent tuberculosis infection among the TB contacts in Shanghai, China. J Infect. 2012;65(1):39-48.
39. Lebwohl M, Yeilding N, Szapary P, et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol. 2010;63(4):571-579.
40. Zhang C, Zhu KJ, Zheng HF, et al. The effect of overweight and obesity on psoriasis patients in Chinese Han population: a hospital-based study. J Eur Acad Dermatol Venereol. 2011;25(1):87-91.
41. Tsai TF, Ho V, Song M, et al; PHOENIX 1, PHOENIX 2, ACCEPT, PEARL and Japanese Ustekinumab Study Groups. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol. 2012;167(5):1145-1152.
42. Haroon M, Martin U, Devlin J. High incidence of intolerance to tuberculosis chemoprophylaxis. Rheumatol Int. 2012;32(1):33-37.
43. Bray MG, Poulain C, Dougados M, Grossec L. Frequency and tolerance of antituberculosis treatment according to national guidelines for prevention of risk of tuberculosis due to tumor necrosis factor blocker treatment. Joint Bone Spine. 2010;77(2):135-141.
44. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA. 1999;281(11):1014-1018.
45. Lin HW, Wang KH, Lin HC, Lin HC. Increased risk of acute myocardial infarction in patients with psoriasis: a 5-year population-based study in Taiwan. J Am Acad Dermatol. 2011;64(3):495-501.
46. Xiao J, Chen LH, Tu YT, Deng XH, Tao J. Prevalence of myocardial infarction in patients with psoriasis in central China. J Eur Acad Dermatol Venereol. 2009;23(11):1311-1315.
47. Chen YJ, Wu CY, Chen TJ, et al. The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan. J Am Acad Dermatol. 2011;65(1):84-91.
48. Reich K, Papp KA, Griffiths CE, et al; PHOENIX 1, PHOENIX 2, and ACCEPT investigators. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol. 2012;11(3):300-312.